Hospira Hinges Emerging Market Success On Scale And Differentiation
This article was originally published in PharmAsia News
Executive Summary
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan
You may also be interested in...
Emerging Views On Emerging Markets: Sanford C. Bernstein & Co. Strategic Decisions Conference
PharmAsia News takes a closer look at presentations by BMS, Celgene, Lilly and Hospira.
A Closer Look At China’s 2012 Essential Drug Expansion
China is likely to focus on drugs with large consumption patterns for the revised EDL, including anti-hypertensive drugs and oncology drugs.
A Closer Look At China’s 2012 Essential Drug Expansion
China is likely to focus on drugs with large consumption patterns for the revised EDL, including anti-hypertensive drugs and oncology drugs.